NEO-DELTA-CORTEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEO-DELTA-CORTEF (NEO-DELTA-CORTEF).
Corticosteroid with potent anti-inflammatory, immunosuppressive, and antiallergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; undergoes reduction, hydrolysis, and conjugation; metabolites excreted in urine and bile. |
| Excretion | Renal: 70-80% as metabolites; biliary: 10-15%; fecal: <5% |
| Half-life | Prednisolone: 2-4 hours; clinical context: adrenal suppression lasts 24-36 hours, requiring tapering |
| Protein binding | Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG) and albumin; prednisone: 70% bound to CBG |
| Volume of Distribution | Prednisolone: 0.4-1.0 L/kg; clinically indicates extensive distribution into tissues |
| Bioavailability | Oral: 70-90% (prednisone converted to prednisolone); IM: 100% |
| Onset of Action | IV: 1-2 minutes; IM: 1-2 hours; oral: 1-2 hours; topical: rapid (minutes) for anti-inflammatory effect |
| Duration of Action | IV: 2-4 hours; oral: 12-36 hours (due to HPA axis suppression); topical: 2-4 hours per application; clinical note: duration depends on dose and duration of therapy |
| Molecular Weight | 360.44 |
1-2 drops into the conjunctival sac every 1-2 hours during the day and every 2 hours at night initially, then reduce frequency as inflammation subsides.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific dosage adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | 1 drop into the conjunctival sac every 1-2 hours; use lowest effective dose for shortest duration. |
| Geriatric use | No specific dose adjustment; monitor for increased intraocular pressure and corticosteroid adverse effects. |
| 1st trimester | Use only if potential benefit justifies risk. Corticosteroids are associated with increased risk of cleft palate at doses >10 mg/day. Monitor for adrenal insufficiency in neonates. |
| 2nd trimester | Use only if clearly needed. May cause fetal growth restriction and adrenal suppression. Prolonged use may lead to premature birth. |
| 3rd trimester | Use with caution. Risk of neonatal adrenal suppression, growth retardation, and possible premature delivery. Avoid high doses near term. |
Clinical note
Comprehensive clinical and safety monograph for NEO-DELTA-CORTEF (NEO-DELTA-CORTEF).
| Placental transfer | Crosses the placenta; metabolized to inactive prednisone. Fetal levels are about 10-15% of maternal levels. Degree of transfer increases with higher doses and prolonged use. |
| Breastfeeding | Prednisolone is excreted into breast milk in low amounts. At maternal doses up to 80 mg/day, infant exposure is minimal (<0.1% of maternal dose). No adverse effects reported, but monitor infant for growth and development with prolonged high-dose therapy. |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionsKnown hypersensitivity to prednisolone or any component
| Precautions | Increased intraocular pressure (IOP) with prolonged use; monitor IOP., Corneal thinning and perforation risk, especially in keratitis., Cataract formation with long-term use., Suppression of local immune response; risk of secondary infections (e.g., fungal, viral)., Systemic absorption possible with extensive use; adrenal suppression unlikely but caution in large doses. |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions required. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (approximately 3-5 fold increase, absolute risk 0.1-0.2%). Second and third trimesters: Risk of intrauterine growth restriction, adrenal suppression, and potential hypothalamic-pituitary-adrenal axis suppression in neonate. Chronic use may lead to oligohydramnios due to fetal renal effects. |
| Fetal Monitoring | Monitor maternal blood pressure and glucose levels due to corticosteroid effects. Assess fetal growth via ultrasound if used chronically. Newborns exposed in utero should be monitored for adrenal insufficiency, hypocalcemia, and signs of infection. |
| Fertility Effects | No direct evidence of impaired fertility. High-dose corticosteroids may disrupt menstrual cycle and ovulation transiently. Neomycin and polymyxin B are not known to affect fertility. |
| Contains prednisolone acetate (anti-inflammatory) and neomycin sulfate (antibiotic). Avoid prolonged use (>10 days) due to risk of secondary infections, increased intraocular pressure, and cataract formation. Use with caution in patients with corneal thinning disorders. Do not use in active viral infections (e.g., herpes simplex) or fungal diseases. Shake suspension well before instillation. Monitor intraocular pressure if used for >10 days. |
| Patient Advice | Shake the bottle vigorously before each use. · Wash hands before instilling drops. Avoid touching the dropper tip to any surface. · Remove contact lenses before use; wait at least 15 minutes before reinserting. · Do not use for longer than prescribed; prolonged use may cause eye damage. · Report any eye pain, vision changes, or worsening redness to your healthcare provider. · Do not share this medication with others. |